



Cancer Molecular Therapeutics Research Association

2026 Annual Meeting

Snowbird Resort | July 12-16, 2026

Program and Schedule

Sunday, July 12

Day 1

4:00-6:00 pm **Registration & Check-In**

Main Lobby

6:00-7:00 pm **Dinner**

Wasatch Room

7:30-7:45 pm **Welcome and Introduction**

*Dr. Martin McMahon, PhD; CMTRA Board President
Senior Director for Preclinical Translation, Huntsman Cancer Institute &
Cumming Professor of Dermatology, University of Utah
Superior Room*

7:45-8:45 pm **Keynote Speaker: "Predictive Oncology: Decoding Genomic, Host, and Immune Determinants of Cancer Progression."**

*Christina Curtis, PhD, MSc
RZ Cao Professor of Medicine, Genetics & Biomedical Science
Stanford University*

9:00-10:30 pm **Welcome Reception**

Wasatch Room

Monday, July 13

Day 2

7:30-8:15 am **Breakfast**

Wasatch Room

8:30 am-12:00 pm **Morning Session: Novel Approaches to Targeting Cancer Vulnerabilities**

*Discussion Leader: Bob Abraham, PhD; CMTRA Board Member
CSO, Engine Biosciences
Superior Room*

8:30-8:45 am **Session Introduction**

Bob Abraham, PhD

8:45-9:15 am **"Activation Lethality: A New Approach to Targeted Therapy"**

*Matt Niederst, PhD
VP, Head of Biology
Delphia Therapeutics*

Monday, July 13 continued

Day 2

9:15-9:45 am	Open Discussion
9:45-10:00 am	Coffee Break <i>Superior Lobby</i>
10:00-10:30 am	“RIPTACs: A Novel, Powerful Modality to Treat Patients with Prostate Cancer and Other Diseases” <i>Edmond Chipumuro, PhD Director, Target Biology Halda Therapeutics</i>
10:30-11:00 am	Open Discussion
11:00-11:30 am	“Targeting the Inverted Proteome” <i>Corleone Delaveris, PhD Co-founder Inversion Therapeutics</i>
11:30 am-12:00 pm	Open Discussion
12:00-1:00 pm	Lunch <i>Superior Lobby</i>
1:00-5:00 pm	Open afternoon for networking <i>Activities at Snowbird: swimming, tram rides, mountain biking, hiking, spa, etc. See hotel for more info.</i>
5:00-6:30 pm	Poster Session and Social <i>Superior Lobby</i>
6:30-7:30 pm	Dinner <i>Superior Lobby</i>
7:30-9:45 pm	Evening Session: Lineage Plasticity in Cancer <i>Discussion Leader: Aria Vaishnavi, PhD; CMTRA Board Member Assistant Professor, Dept. of Genetics MD Anderson Cancer Center Superior Room</i>
7:30-7:45 pm	Session Introduction <i>Aria Vaishnavi, PhD</i>
7:45-8:15 pm	“Modeling Lineage Plasticity and Metastasis in Prostate Cancer” <i>Cory Abate-Shen, PhD Professor of Urological Oncology Columbia University</i>
8:15-8:45 pm	Open Discussion
8:45-9:15 pm	“Non-canonical PI3K-gamma signaling is a lineage-specific vulnerability of tuft-like cancer” <i>Trudy Oliver, PhD Professor of Pharmacology and Cancer Biology Duke University</i>
9:15-9:45 pm	Open Discussion

Monday, cont'd | Tuesday, July 14

Day 3

10:00 pm

Social*Hospitality Suite- Mt. Superior Room*

7:30-8:15 am

Breakfast*Superior Lobby*8:30 am-
12:00 pm**Morning Session: Pancreatic Ductal Adenocarcinoma***Discussion Leader: Martin McMahon, PhD; CMTRA Board President
Huntsman Cancer Institute
Superior Room*

8:30-8:45 am

Introduction*Martin McMahon, PhD*

8:45-9:15 am

“Evolution of the pancreatic cancer microenvironment”*Marina Pasca di Magliano, PhD
Professor of Surgery, Surgical Immunology & Cell and Developmental Biology
University of Michigan*

9:15-9:45 am

Open Discussion

9:45-10:00 am

Group Photograph and Coffee Break*Superior Lobby*10:00-10:30
am**“Organelle based adaptive mechanisms during pancreatic cancer metastasis”***Rushika Perera, PhD
Professor, Department of Anatomy, School of Medicine
UC San Francisco*10:30-11:00
am**Open Discussion**11:00-11:30
am**“Clonal Heterogeneity in Human Pancreatic Cancer: Impact on Tumor Progression”***Diane Simeone, MD
Professor of Surgery
UC San Diego*11:30 am-
12:00 pm**Open Discussion**

12:00-1:00 pm

Lunch*Superior Lobby*

1:00-5:00 pm

Open afternoon for networking- World Cup Semifinals in Hospitality Suite*Activities at Snowbird: swimming, tram rides, mountain biking, hiking, spa, etc. See hotel for more info.*

5:00-6:30 pm

Panel Discussion: Artificial Intelligence & Machine Learning in Cancer Research*Discussion Leader: Hans Bitter/Emma Lees
Panelists:
Surge Biswas- Nabla Bio
Elliot Hershberg- Amplify
Ian Quigley- Leash Bio*

6:30-7:30 pm

Dinner*Superior Lobby*

Tuesday, July 14, continued

Day 3

7:30-9:45 pm	Evening Session: Hormone-Dependent Cancers Discussion Leader: Melissa Junttila, PhD Vice President, Head of Biology Oric Pharmaceuticals Superior Room
7:30-7:45 pm	Introduction Discussion Leader: Melissa Junttila, PhD
7:45-8:15 pm	“Modeling Breast Cancer to Advance Therapeutic Strategies” Alana Welm, PhD Chair and Professor, Department of Oncological Sciences University of Utah and Huntsman Cancer Institute
8:15-8:45 pm	Open Discussion
8:45-9:15 pm	“Understanding the mechanisms by which cells recognize and respond to different levels of androgens has informed new therapeutic approaches for prostate cancer” Donald McDonnell, PhD Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, Professor of Pharmacology and Cancer Biology, Professor in Medicine, Professor of Cell Biology Duke University
9:15-9:45 pm	Open Discussion
9:45 pm	Social Hospitality Suite- Mt. Superior Room

Wednesday, July 15

Day 4

7:30-8:15 am	Breakfast Superior Lobby
8:30 am-12:00 pm	Morning Session: Cancer Cell Stress & Drug Resistance Discussion Leader: Ralph De Berardinis, MD, PhD; CMTRA Board Member Director of the Eugene McDermott Center for Human Growth and Development; Director, Genetic and Metabolic Disease Program UT Southwestern Superior Room
8:30-8:45 am	Introduction Ralph De Berardinis, PhD
8:45-9:15 am	“Ferroptosis and the metastatic microenvironment” Jessalyn Ubellacker, MD, PhD Assistant Professor, Department of Molecular Metabolism Harvard T.H. Chan School of Public Health
9:15-9:45 am	Open Discussion
9:45-10:00 am	Coffee Break Superior Lobby

Wednesday, July 15, continued

Day 4

10:00-10:30 am	"Molecular Glues in endogenous signaling and cancer therapy." Michael Rapé, PhD Professor, Division of Molecular Therapeutics UC Berkeley
10:30-11:00 am	Open Discussion
11:00-11:30 am	"Exploiting Genomic and Lineage-State Vulnerabilities in Small Cell Lung Cancer" Matthew Oser, MD, PhD Associate Professor of Medicine Dana Farber Cancer Institute
11:30 am-12:00 pm	Open Discussion
12:00-1:00 pm	Lunch Superior Lobby
1:00-2:00 pm	Break- World Cup Semifinals Broadcast in Hospitality Suite
2:00-5:00 pm	Afternoon Session: Chemical Biology Discussion Leader: Matt Patricelli, PhD; CMTRA Board Member Chief Scientific Officer Vividion Therapeutics Superior Room
2:00-2:15 pm	Introduction Matt Patricelli, PhD
2:15-2:45 pm	"Expanding the Chemical Tractability of the Human Proteome" Chris Parker, PhD Professor, Department of Chemistry Scripps Research
2:45-3:10 pm	Open Discussion
3:10-3:40 pm	"Chemical and genetic glues of the E3 ligase oncogene KBTBD4" Brian Liao, PhD Associate Professor, Department of Chemistry and Chemical Biology Harvard University
3:40-4:05 pm	Open Discussion
4:05-4:35 pm	"Interrogating the Druggable Proteome with Proximity Pharmacology" Fleur Ferguson, PhD Assistant Professor of Chemistry and Biochemistry UC San Diego
4:35-5:00 pm	Open Discussion
5:00-6:00 pm	Break

Wednesday, July 15, continued

Day 4

6:00-7:00 pm **Dinner**
Superior Lobby

7:15-8:15 pm **Closing Keynote: "How cancer cells escape targeted therapy by changing identity"**
*Charles Sawyers, PhD
HHMI Investigator, Chair of Human Oncology and Pathogenesis Program
Memorial Sloan Kettering Cancer Center
Superior Room*

8:30-10:00 pm **Closing Reception**
Superior Lobby

Thursday, July 16

Day 5

Onsite breakfast options:

*The Atrium- Cliff lodge
Seventy One- Cliff Lodge
Creekside Cafe + Grill- Snowbird Center
General Gritts Bodega- Snowbird Center
Sidecar Coffee- Snowbird Center
Baked and Brewed Coffee- Snowbird Center*

11:00 am **Departure & Checkout**
Check out time: 11:00 am

IMPORTANT NOTICE: By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photographing or recording of sessions, posters or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers.

"THIS MEETING WOULD NOT BE POSSIBLE WITHOUT THE GENEROUS CONTRIBUTIONS FROM OUR MANY FRIENDS AND COLLEAGUES IN THE PRIVATE BIOTECH/PHARMACEUTICAL SECTOR"

**CANCER MOLECULAR THERAPEUTICS RESEARCH ASSOCIATION
ANNUAL CONFERENCE 2026**



CMTRA

The Cancer Molecular Therapeutics
Research Association

Thanks to our 2026 sponsors:

AstraZeneca 


ATAVISTIK

BBOTi
BridgeBio Oncology Therapeutics

 Bristol Myers Squibb®

Genentech
The original biotech company

 GILEAD

 NOVARTIS

Lilly

 Pfizer

 Revolution
Medicines

SUTRO 
BIOPHARMA

vividion TM
THERAPEUTICS

1	Kayla Nutsch, PhD	kayla.nutsch@bbotx.com	BBOT	BBO-11818: an orally bioavailable, highly potent and selective non-covalent pan-KRAS(ON) and (OFF) inhibitor with robust anti-tumor activity in KRAS-mutant preclinical models
2	Reilly Falter	reilly.falter@hci.utah.edu	HCI	SOX2 is a master regulator of classical squamous cell carcinoma
3	Karsten Eastman	karsten@setheratx.com	Sethera	High-Throughput Discovery of Polymacrocyclic Peptides for Targeting Oncologic Drivers
4	Kate Warde	kate.warde@hci.utah.edu	HCI	“Androgens promote anti-tumor immunity in adrenal cancer”
5	Sanjana Srinivas Boggaram	sanjana.boggaram@hci.utah.edu	HCI	Investigating the role of AKT protein kinases in lung cancer.
6	Hannah Neuendorf	hannah.neuendorf@hci.utah.edu	HCI	‘Investigating the role of the NRAS ó PI3’Kα signaling axis in NRAS-driven melanoma’.
7	Maha Moussa	"maha.moussa@usu.edu	USU	Leakage-Controlled Deep Learning for Prostate Cancer Histopathology: A Case-Aware Comparison of Majority-Vote and Soft-Label Supervision
8	Said Elshafae	u6053028@uemail.utah.edu	HCI	CD79b SynNotch-Gated CD19 BBζ CAR-T Cells Sustain Anti-Leukemia Activity and Preserve T-Cell Fitness in B-ALL
9	Yi Qiao	yi.qiao@utah.edu	HCI	A generalizable software framework for ultra-rapid sequence analysis and its application in enabling 1 day deep multi-omic data analysis turnaround for brain cancer precision oncology
10	Henry Arnold	henry.arnold@hci.utah.edu	HCI	Investigating the impact of oncogenic signaling on pulmonary and gastrointestinal identity programs in lung adenocarcinoma
11	Melissa Junttila	melissa.junttila@oricpharma.com	Oric Pharma	PRC2 Inhibition Enhances AR Inhibitor Response to Delay Treatment Relapse in Castration-Sensitive Prostate Cancer by Restricting Adaptation of Tumor Cells in Preclinical Studies
12	Headtlove Essel Dadzie	Headtlove.esseldadzie@hci.utah.edu	HCI	HNF4α controls lineage identity and therapeutic response in Invasive Mucinous Adenocarcinoma of the lung.
13	Bill Schary	bill@7hillspharma.com	7 Hills Pharma	A phase 1b dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of alintegimod (ALIN) + ipilimumab (Ipi) followed by nivolumab (Nivo) in advanced solid tumor patients
14	Brandon Murphy	brandon.murphy@hci.utah.edu	HCI	Delineating the mechanisms enabling lung adenocarcinomas to overcome dependence on WNT/β-catenin signaling
15	Beatrice Knudsen	beatrice.knudsen@path.utah.edu	HCI	FoxA2 and ONECUT2 mIF Phenotypes in Prostate Cancer
16	Tessa Tolson	u1588998@utah.edu	UU	Identification and phenotypical evaluation of androgen receptor indifferent phenotype in treatment-naïve primary prostate cancer cases
17	Mona Foth	mona.foth@hci.utah.edu	HCI	Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma
18	Maha Moussa	maha.moussa@usu.edu	Utah State University	Leakage-Controlled Deep Learning for Prostate Cancer Histopathology: A Case-Aware Comparison of Majority-Vote and Soft-Label Supervision

CMTRA 2026 Delegates

Cory	Abate-Shen	cabateshen@columbia.edu	Professor	Columbia University
Bob	Abraham	bob.abraham@enginebio.com	Chief Scientific Officer	Engine Biosciences
Henry	Arnold	Henry.Arnold@hci.utah.edu	PhD Candidate	University of Utah/ Huntsman Cancer Institute
Semiha Kevser	Bali	bali2@llnl.gov	Postdoctoral Researcher	Lawrence Livermore National Laboratory
Kaitlin	Basham	kaitlin.basham@hci.utah.edu	Assistant Professor	University of Utah, Huntsman Cancer Institute
Tessa	Bass	u1588998@utah.edu	PhD	University of Utah
Surojit	Biswas	surge@nabla.bio	Co-founder/CEO	Nabla Bio
Hans	Bitter	hans.bitter@takeda.com	Head of Computational Science & Data Strategy	Takeda Pharmaceuticals
Edmond	Chipumuro	echipumuro@gmail.com	Ph.D.	Halda Therapeutics
Christina	Curtis	cncurtis@stanford.edu	Professor of Medicine, Genetics, and Biomedical Data Science	Stanford University
Gauri	Deb	gauri.deb@bms.com	PhD	Bristol Myers Squibb
Ralph	DeBerardinis	ralph.deberardinis@utsouthwestern.edu	Professor	UT Southwestern Medical Center
Corleone	Delaveris	cdelaveris@inversiontx.com	Co-Founder	Inversion Therapeutics
Karsten	Eastman	karsten@setheratx.com	Cofounder&CEO	Sethera Therapeutics
Said	Elshafae	said.elshafae@utah.edu	Research Assistant Professor	University of Utah
Headtlove	Essel Dadzie	Headtlove.Esseldadzie@utah.edu	Graduate Research Assistant	University of Utah/ Huntsman Cancer Institute
Reilly	Falter	reilly.falter@utah.edu	PhD Candidate	Huntsman Cancer Institute

CMTRA 2026 Delegates

Fleur	Ferguson	fleur.m.ferguson@gmail.com	Assistant Professor	UCSD
Mona	Foth	mona.foth@hci.utah.edu	PhD	Huntsman Cancer Institute
Silvia	Goldoni	silvia.goldoni@bayer.com	Director	Bayer Pharmaceutical USA
Julie	Grant	jgrant@canaan.com	General Partner	Canaan
Anna	Guarnieri	anna.guarnieri@cogentbio.com	Associate Director, Cell Biology & Translational Science	Cogent Biosciences
Tonia	Hafner	hafnera4@gene.com	Principal Scientist	Genentech
Elliot	Hershberg	Elliot@amplifypartners.com	PhD	Amplify Partners
Hannah	Hubert	hannahhubert@cogentbio.com	MS, Senior Associate Scientist	Cogent Biosciences
Parker	Irvin	u1443188@uemail.utah.edu	Graduate Research Assist (RA)	Huntsman Cancer Institute
Melissa	Junttila	melissa.junttila@oricpharma.com	VP, Head of Biology	ORIC Pharmaceuticals, Inc.
Sharanya	Kalasekar	sharanya.kalasekar@hci.utah.edu	PhD	Huntsman Cancer Institute
Charles	Keller	charles@cc-tdi.org	Scientific Director	Children's Cancer Therapy Development Institute
Conan	Kinsey	Conan.Kinsey@hci.utah.edu	MD, PhD	Huntsman Cancer Institute
Emma	Lees	emma.lees@bms.com	SVP, Oncology Research	Bristol Myers Squibb
Brian	Liau	liau@fas.harvard.edu	Associate Professor	Harvard University
Felice	Lightstone	lightstone1@llnl.gov	PhD	Lawrence Livermore National Laboratory
Shiva	Malek	shiva.malek@novartis.com	Global Head, Oncology Disease Area	Novartis Biomedical Research, Inc.

CMTRA 2026 Delegates

Upendra	Marathi	upendra@7hillspharma.com	President	7 Hills Pharma
Donald	McDonnell	donald.mcdonnell@duke.edu	Professor	Duke University School of Medicine
Martin	McMahon	martin.mcmahon@hci.utah.edu	Senior Director, Preclinical Translation	Huntsman Cancer Institute
Brandon	Murphy	brandon.murphy@hci.utah.edu	Postdoctoral Fellow	Huntsman Cancer Institute
Mark	Nelson	mnelson1862@gmail.com	Consultant, Business and Science Development	Asinex Corporation
Hannah	Neuendorf	hannah.neuendorf@hci.utah.edu	Postdoc	Huntsman Cancer Institute, University of Utah
Matt	Niederst	matt.niederst@delphiatx.com	VP, Head of Biology, PhD	Delphia
Kayla	Nutsch	Kayla.Nutsch@bbotx.com	Associate Scientist	BBOT
Trudy	Oliver	tgo@duke.edu	George Barth Geller Distinguished Professor for Research in Pharmacology	Duke University
Matthew	Oser	matthew_oser@dfci.harvard.edu	Associate Professor of Medicine	Dana-Farber Cancer Institute
Chris	Parker	cparker@scripps.edu	Professor	The Scripps Research Institute
Marina	Pasca di Magliano	marinapa@umich.edu	Professor	University of Michigan
Matthew	Patricelli	mattp@vividion.com	Chief Scientific Officer	Vividion Therapeutics
Rushika	Perera	rushika.perera@ucsf.edu	Professor	University of California San Francisco
Pranav	Pillai	u6070302@utah.edu	Graduate Student	Huntsman Cancer Institute, University of Utah
Yi	Qiao	yi.qiao@utah.edu	Assistant Professor	Biomedical Informatics, University of Utah
Ian	Quigley	ian@leash.bio	CEO/Cofounder	Leash Biosciences

CMTRA 2026 Delegates

Michael	Rapé	mraper@berkeley.edu	Investigator, HHMI	UC Berkeley, HHMI
Charles	Sawyers	sawyersc@mskcc.org	Investigator, Howard Hughes Medical Institute; Chair, Human Oncology and Pathogenesis Program	Memorial Sloan Kettering Cancer Center
William	Schary	bill@7hillspharma.com	Vice President, Clinical and Regulatory Affairs	7HillsPharma, Inc.
Samuel	Scott	one800samuel@gmail.com	PhD Student	Hunstman Cancer Institute
Kathleen	Seyb	kathleen.seyb@trianabio.com	SVP, Biology and Translational Sciences	Triana Biomedicines
Zahid	Siddik	zsiddik@mdanderson.org	Professor	UT MD Anderson Cancer Center
Diane	Simeone	dsimeone@health.ucsd.edu	Director	Moore's Cancer Center
Ben	Spike	benjamin.spike@hci.utah.edu	Associate Professor	University of Utah/Huntsman Cancer Institute
Sanjana	Srinivas Boggaram	sanjana.boggaram@hci.utah.edu	PhD student	University of Utah
Jessalyn	Ubellacker	jubellacker@hsph.harvard.edu	Assistant Professor (PhD, MD)	Harvard T.H. Chan School of Public Health
Aria	Vaishnavi	avaishnavi1@mdanderson.org	Assistant Professor	University of Texas MD Anderson Cancer Center
Eli	Wallace	eliwallace.1@gmail.com		
Kate	Warde	kate.warde@hci.utah.edu	Postdoc	Huntsman Cancer Institute, University of Utah
Alana	Welm	alan.welm@hci.utah.edu	Professor	University of Utah, Huntsman Cancer Institute
Jared	Wieland	jared.a.wieland@gmail.com	CSO and Student at BYU	Indel Bioinnovations and BYU
Wen-I	Wu	weni.wu@medsyin.com	VP	Medsyin
Jörg	Zeller	joergz@med.umich.edu	Professor	University of Michigan